Skip to Content
MilliporeSigma
  • Doxorubicin induces senescence and impairs function of human cardiac progenitor cells.

Doxorubicin induces senescence and impairs function of human cardiac progenitor cells.

Basic research in cardiology (2013-02-16)
Elena Piegari, Antonella De Angelis, Donato Cappetta, Rosa Russo, Grazia Esposito, Sarah Costantino, Gallia Graiani, Caterina Frati, Lucia Prezioso, Liberato Berrino, Konrad Urbanek, Federico Quaini, Francesco Rossi
ABSTRACT

The increasing population of cancer survivors faces considerable morbidity and mortality due to late effects of the antineoplastic therapy. Cardiotoxicity is a major limiting factor of therapy with doxorubicin (DOXO), the most effective anthracycline, and is characterized by a dilated cardiomyopathy that can develop even years after treatment. Studies in animals have proposed the cardiac progenitor cells (CPCs) as the cellular target responsible for DOXO-induced cardiomyopathy but the relevance of these observations to clinical settings is unknown. In this study, the analysis of the DOXO-induced cardiomyopathic human hearts showed that the majority of human CPCs (hCPCs) was senescent. In isolated hCPCs, DOXO triggered DNA damage response leading to apoptosis early after exposure, and telomere shortening and senescence at later time interval. Functional properties of hCPCs, such as migration and differentiation, were also negatively affected. Importantly, the differentiated progeny of DOXO-treated hCPCs prematurely expressed the senescence marker p16(INK4a). In conclusion, DOXO exposure severely affects the population of hCPCs and permanently impairs their function. Premature senescence of hCPCs and their progeny can be responsible for the decline in the regenerative capacity of the heart and may represent the cellular basis of DOXO-induced cardiomyopathy in humans.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
β-Galactosidase from Escherichia coli, suitable for enzyme immunoassay, lyophilized, powder, ~140 U/mg
Sigma-Aldrich
β-Galactosidase from Escherichia coli, aqueous glycerol suspension, ≥500 units/mg protein (biuret)
Sigma-Aldrich
β-Galactosidase from bovine liver, Grade III, lyophilized powder, ≥0.15 units/mg protein
Sigma-Aldrich
β-Galactosidase from Escherichia coli, lyophilized powder, ≥500 units/mg protein
Sigma-Aldrich
β-Galactosidase from Escherichia coli, Grade VI, lyophilized powder, ≥250 units/mg protein
Sigma-Aldrich
β-Galactosidase from Escherichia coli, Grade VIII, lyophilized powder, ≥500 units/mg protein
Sigma-Aldrich
β-Galactosidase from bovine testes, ammonium sulfate suspension, 1.0-3.0 units/mg protein (modified Warburg-Christian)
Sigma-Aldrich
β-Galactosidase from Aspergillus oryzae, ≥8.0 units/mg solid